• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Know Labs has more positive data for its non-invasive glucose monitor

July 26, 2023 By Sean Whooley

Know Labs non-invasive blood glucose monitor device
The Gen 1 prototype device. [Image courtesy of Know Labs]
Know Labs (NYSE:KNW) today announced results from a new study that further demonstrate the accuracy of its Bio-RFID sensor technology.

Last month, the company unveiled the prototype for its proprietary non-invasive sensor technology. Its proprietary Bio-RFID technology uses spectroscopy to direct electromagnetic energy through a substance or material. Through this, it can capture a unique molecular signature. The Know Labs technology integrates into wearable, mobile or bench-top form factors.

Seattle-based Know Labs’ study showed that continued algorithm refinement and more high-quality data improved the sensor’s accuracy. Results included in an overall mean absolute relative difference (MARD) of 11.3%.

The study assessed the ability of the Bio-RFID sensor to non-invasively and continuously quantify blood glucose. It used the Dexcom G6 CGM as a reference device. The study completed its data collection in May of this year, according to a news release.

Know Labs applied novel data preprocessing techniques and trained a light gradient-boosting machine (lightGBM) model. This predicted blood glucose values using 3,311 observations (or reference device values) from more than 330 hours of data. Thirteen healthy subjects participated.

With this method, Know Labs predicted blood glucose in the test set with a MARD of 11.3%. Comparatively, the company shared study results in May from 1,555 observations over 130 hours with a MARD of 12.9%.

The company continues testing for its first-generation sensor prototype with an eye on eventually garnering FDA clearance. It said it wants to collect more high-quality, high-resolution data across a diverse participant population.

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: Know Labs

IN CASE YOU MISSED IT

  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications
  • Go-Pen ApS wins FDA nod for user-filled insulin pen

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS